Its all right there in the latest tron financial in plain sight.
Speaking of tron financials, there are a lot of items I find concerning.
Only a few” of them are found below.
NOTE TO READER
The Company has retained the services of a professional accountant to assist in the preparation of its current period financial statements and the notes thereto. During the course of a review of previously published financial data and reports, the independent accountant discovered several errors in previously applied accounting treatment and presentation. The data contained in these reports include various adjustments and restatements of certain prior period data including the following key adjustments:
- Revaluation of 400,000,000 shares issued in respect to the acquisition of ImedScan;
- Write down of the value of share issued for ImedScan previously reported as an asset;
- Reclassification of the prior operations of the Company as discontinued to reflect defunct operating segment;
- Restatement of the valuation of certain shares issued for debt and the associated reduction to accounts payable.
In addition to these revisions, the Company has revised the presentation of its financial statements and notes thereto to fully comply with general accepted acco5unting principles in the United States (US GAAP) in order to include a statement of stockholders’ equity (deficiency) and appropriate prior period comparative data.
Subsequent to the period covered by this report, the Company has agreed to issue a total of 2,500,000 shares of Series A Preferred stock to Massimo Travagli as consulting fees in respect to ongoing negotiations with various entities that the Company intends to acquire in fiscal 2020. Each share of Series A Preferred Stock is entitled to 200 votes per share on any matters voted on by the holders of the Company’s common stock and is convertible into common stock on the basis of one (1) shares of common stock for each 1 share of Series A Preferred Stock held. The shares of Series A Preferred Stock are anti-dilutive to reverse splits.
As at January 31, 2019, the Company has recorded a loss on acquisition in the amount of $3,400,000 in respect to the acquisition of iMedScan in fiscal 2017. The recorded loss which reflects the fair market value of the 400,000,000 shares issued to shareholders of Pantheon as at the acquisition date, or $0.0085 per share.
And of course there is POS H wayne hayes :
On June 13, 2017 H wayne hayes’s Patienttrac received 70,000,000 shares free trading stock Priced at .0007 at time of issuance
On Sept 1, 2018 $50,000 note and $2200 in accrued interest with a maturity date of Sept 1 , 2019 H wayne hayes’s Patienttrac - loan for imed scan.
Note:The convertible loan disclosed above has been reported in financial disclosures by the former management of the Company. Prior disclosures indicate the amounts reflected above were provided in respect to the acquisition of defunct subsidiary, iMedScan Corporation. Current management has been unable to obtain copies of the original convertible note or to verify details of the advance of the reported proceeds in order to confirm the exact terms of the loan or to verify proceeds. Management has determined to include this convertible loan as a part of the discontinued operations reflected in our current period financial statements. It has been assumed by current management that shares issued to PatientTrac as reported in the current financial reports settled this outstanding convertible loan in full.
On Oct 2, 2018 H wayne hayes’s Patienttrac received 81,000,000 shares free trading stock Priced at .001 at time of issuance
On August 19, 2019, the Company advanced $12,500 to PatientTrac Limited, a shareholder of the Company as a loan.
AI
Market Data 
Markets 
